Davos Life Science is pleased to announce the launch of our newly developed product: Naturale3 Bio-Enhanced 20, the epitome of the SEDDS (self-emulsifying delivery system) formula that gives at least 2 times higher bio-availability than competition.
Upon ingestion, Naturale3 Bio-Enhanced 20 forms micro/nano emulsion in the gut which enables high absorption into the body and reduces breakdown in the liver, independent of dietary fat or food intake. Davos Life Science R&D validated that Naturale3 Bio-Enhanced 20 delivers tocotrienol at consistently much higher levels than current commercially available product.
Vitamin E is widely recognized as an important lipid-based antioxidant that mainly protects unsaturated fatty acids on cell membranes. Although α-tocopherol is recognized as the isoform with the highest vitamin E activity, tocotrienol has been shown to have much higher free radical scavenging ability than α-tocopherol within the cell1. This is due to the higher penetration of tocotrienol molecules into the cell while α-tocopherol mainly resides on the plasma membrane based on Davoslife in-house research. As such tocotrienol is able to protect important organelles like the mitochondria (responsible for energy production) and DNA (genetic code) from oxidative stress induced damage better than α-tocopherol.
Increasingly, recent studies show that tocotrienol but not α-tocopherol shows better clinical benefits in cardiovascular, brain, liver & women’s health. Numerous studies indicate that cholesterol & triglyceride levels can be controlled with prolonged consumption of palm-derived tocotrienol with the effect mainly due to gamma & delta tocotrienol2. These two tocotrienol isomers are also responsible for controlling inflammatory responses in the body especially in conditions like metabolic syndrome, pre-diabetes, obesity, fatty liver etc3. Alpha tocotrienol which is abundant in palm had been extensively researched for brain health benefits including reduction of post-stroke injury and recovery4. A recent study also found that patients with mild cognitive impairment & Alzheimer’s disease have low levels of vitamin E in their blood plasma, in particular alpha & gamma tocotrienol5.
Although vitamin E in general has been well studied for their absorption and metabolic fate, the plasma concentration of tocotrienol was found to be much lower compared to tocopherols6. Absorption of tocotrienol in humans is enhanced in the presence of a high fat diet but there is large variability in absorption efficiency between individuals. Davos Life Science proprietary formulation – Bio-Enhanced 20 overcomes this problem by consistently delivering tocotrienol at high amount in the plasma.
Naturale3 Bio-Enhanced 20 will be the preferred formula for brand owners and manufacturers of dietary supplements as it enables the full benefits of tocotrienol to be achieved for all health concerns via its optimized delivery system
About Davos Life Science
Davos Life Science is established in 2004, wholly owned subsidiary of Kuala Lumpur Kepong Berhad (KLK), a Bursa Malaysia Main Board listed company involved in the exploration of palm oil plantations worldwide. It is also vertically integrated with KLK Plantations & KLK Manufacturing Division (KLK Oleo) for its supply of palm tocotrienols. It researches on the health benefits of palm tocotrienol extracted through its dedicated state of the art proprietary manufacturing facilities & technology.
Davos Life Science’s tocotrienol is widely recognized by leading international nutraceutical and cosmeceutical companies under the brand name, Naturale³. To explore the benefits and applications of Naturale³, please visit www.davoslife.com.
For scientific information, please visit www.tocotrienolresearch.org
All enquiries should be directed to: Ms Mary Kueh, General Manager of Sales & Marketing, Davos Life Science Singapore Pte LtdTel: (603) 7809 8872 Email: email@example.com
1. Persistent Organic Pollutants: A Global Issue, A Global Response. United States Environmental Protection Agency
1. Saito Y et. al. 2004. Annals of the New York Academy of Sciences 1031: 368–75
2. Zaiden N et. al. 2010. J Atherosclerosis Thrombosis 4911:1019–103
3. Wong WY & Brown L 2011. Current Pharmaceutical Design 17: 2206-221
4. Sen et. al. 2010. J Am Coll Nutr. June 29(3 Suppl): 314S–323
5. Mangialasche F et. al. 2013. J Intern Med 273: 602–62
6. Fu JY et. al. 2014. Nutrition & Metabolism 2014, 11:5
Click for more information.